TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy
Yun Sun Lee1, Ji-Yoon Choi1, Jeeyun Lee2
11 Department of Orthopaedic Surgery, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
Abstract:
The anticancer effects of Src kinase inhibitors are controversial. This study found an association between alterations in the TP53 gene and the synergy score for combination treatment with doxorubicin and an Src kinase inhibitor using human osteosarcoma cell lines (MG63 and U2OS) and human colon cancer cell line. Doxorubicin was found to activate signal transducer and activator of transcription 3 via Src kinase in cancer cells harboring alterations in TP53. A drug combination study using patient-derived cells confirmed that an Src kinase inhibitor synergizes with doxorubicin in cancer cells harboring alterations in TP53, while antagonizing its effect in cancer cells expressing wild-type TP53. Our findings suggest that genetic alterations in TP53 are a critical factor in determining the use of a combination treatment of doxorubicin and Src inhibitors.
Insights
Genetic alterations in the TP53 gene influence the effectiveness of combining doxorubicin with Src kinase inhibitors. This combination shows synergy in TP53-altered cancers but antagonism in wild-type TP53 cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- The therapeutic efficacy of Src kinase inhibitors in cancer treatment remains debated.
- The TP53 gene status is a crucial factor in cancer progression and treatment response.
Purpose of the Study:
- To investigate the association between TP53 gene alterations and the synergistic effects of combining doxorubicin with Src kinase inhibitors.
- To determine the role of TP53 in mediating the response to this drug combination.
Main Methods:
- Utilized human osteosarcoma (MG63, U2OS) and colon cancer cell lines.
- Performed drug combination studies with doxorubicin and an Src kinase inhibitor.
- Analyzed TP53 gene status and its impact on drug synergy using patient-derived cells.
Main Results:
- Found a significant association between TP53 alterations and synergistic effects of doxorubicin plus Src kinase inhibitor.
- Doxorubicin activates signal transducer and activator of transcription 3 (STAT3) via Src kinase in TP53-altered cells.
- Src kinase inhibitor synergized with doxorubicin in TP53-altered cells but antagonized effects in wild-type TP53 cells.
Conclusions:
- TP53 genetic alterations are critical determinants for the efficacy of combined doxorubicin and Src inhibitor therapy.
- This finding has implications for personalized cancer treatment strategies based on TP53 mutational status.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Frequency-dependent Selection
Gene Therapy
Drug Dependence
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...


